Skip to main content
Publications
Simpson EL, Eckert L, Gadkari A, Brown TM, Lio PA, Lockshin B, Nelson L, Fehnel SE, Mahajan P, Chao J, Nygardas M, Guillemin I. Evaluating the clinical utility of the Atopic Dermatitis Control Tool: measurement properties and agreement between patients' responses and clinicians' impressions of atopic dermatitis control. Br J Dermatol. 2024 May 17;190(6):917-9. doi: 10.1093/bjd/ljae056
Yosipovitch G, Reaney M, Mastey V, Eckert L, Abbe A, Nelson L, Clark M, Williams N, Chen Z, Ardeleanu M, Akinlade B, Graham NMH, Pirozzi G, Staudinger H, Plaum S, Radin A, Gadkari A. Peak Pruritus Numerical Rating Scale: psychometric validation and responder definition for assessing itch in moderate-to-severe atopic dermatitis. Br J Dermatol. 2019 Oct;181(4):761-9. doi: 10.1111/bjd.17744
Horndler C, Gallego R, Garcia-Albeniz X, Alonso-Espinaco V, Alonso V, Escudero P, Jimeno M, Ortego J, Codony-Servat J, Fernandez-Martos C, Calatrava A, Marín-Aguilera M, Munoz J, Castellví-Bel S, Castells A, Rubini M, Gascon P, Maurel J. Co-expression of matrix metalloproteinase-7 (MMP-7) and phosphorylated insulin growth factor receptor I (pIGF-1R) correlates with poor prognosis in patients with wild-type KRAS treated with cetuximab or panitumumab: a GEMCAD study. Cancer Biol Ther. 2011 Jan 15;11(2):177-83.